Michael Severino, AbbVie vice chairman and president
March 10, 2022 10:18 AM EST
R&D

Look­ing to bat­tle ri­vals in a big mar­ket, Ab­b­Vie is head­ed to the FDA af­ter clear­ing a PhI­II hur­dle for chron­ic mi­graine

John Carroll

Editor & Founder

Ever the ag­gres­sive com­peti­tor, Ab­b­Vie is tak­ing a shot at a sig­nif­i­cant la­bel ex­pan­sion for its mi­graine drug Qulip­ta (ato­gepant) that will give them a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar

Lil­ly pays $10M up­front for Organo­vo’s FXR ag­o­nist pro­gram

Com­pounders sue FDA over re­moval of semaglu­tide from of­fi­cial short­age list

Can­del's vi­ral ther­a­py shows promis­ing sur­vival in small pan­cre­at­ic can­cer study

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times